comparemela.com

Latest Breaking News On - டாரோ மருந்து தொழில்கள் - Page 2 : comparemela.com

Babesiosis Market to Grow at a CAGR of 5% by 2021-2028: Analysed by Business Growth, Development Fac

Babesiosis Market to Grow at a CAGR of 5% by 2021-2028: Analysed by Business Growth, Development Fac
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Taro Announces Resignation of Chief Financial Officer

Taro Announces Resignation of Chief Financial Officer Search jobs Taro Announces Resignation of Chief Financial Officer HAWTHORNE, N.Y. (BUSINESS WIRE) Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities. Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors.”

Sun Pharma Q4 Results: Net Profit Slumps 52% On Lower Other Income, Taro Operating Loss

Sun Pharmaceutical Industries Ltd.’s quarterly profit fell by more than half as sales and other income declined, and its U.S. arm reported an operating loss. Consolidated net profit of the nation’s largest drugmaker fell 52% sequentially to Rs 894.15 crore in the quarter ended March, according to an exchange filing.

Taro: Fiscal Q4 Earnings Snapshot

Taro: Fiscal Q4 Earnings Snapshot May 19, 2021 FacebookTwitterEmail HAIFA BAY, Israel (AP) Taro Pharmaceutical Industries Ltd. (TARO) on Wednesday reported a fiscal fourth-quarter loss of $29.8 million, after reporting a profit in the same period a year earlier. The Haifa Bay, Israel-based company said it had a loss of 78 cents per share. Earnings, adjusted for non-recurring costs, were 81 cents per share. The drug maker posted revenue of $148.3 million in the period. For the year, the company reported a loss of $386.7 million, or $10.12 per share, swinging to a loss in the period. Revenue was reported as $549 million. Taro shares have declined roughly 5% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $69.85, a rise of 3.5% in the last 12 months.

Taro Pharmaceutical Industries : to Announce Full Year Results on May 19, 2021

Message : Required fields Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021. The release will be accessible on Taro’s website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com. © Business Wire 2021 05/20

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.